London Stock Exchange welcomes Poolbeg Pharma plc to AIM

London Stock Exchange welcomes Poolbeg Pharma (‘POLB’) a clinical-stage, infectious disease pharmaceutical company with a novel capital light clinical model to rival the conventional biotech model, as it lists on AIM.

Poolbeg Pharma has raised £25 million and lists with a market capitalisation of £50 million with Schroder Investment Management and other institutions under the disclosable amount taking part in the fundraise. Cathal Friel, Poolbeg Pharma Chairman, also took part in the placing investing £500k signifying the commitment and belief that management have in the business model. The Company is targeting the growing infectious disease market, which in the wake of the COVID-19 pandemic, has become one of the fastest growing and exciting markets with expected market value of $250bn by 2025.  

Poolbeg Pharma’s capital light clinical model aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company has aspirations to become a “one-stop shop” for Big Pharma seeking mid-stage products to license or acquire.

With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg Pharma is headquartered in London. The Company is led by a team with a track record of delivery and creating value for shareholders and has access to one of the largest infectious disease progression data and bio banks i.e. Open Orphan's data and biobank, with the potential to interrogate the data with an AI data analysis platform (active and productive discussions underway) to accelerate the identification of drug targets / products. 

Poolbeg already has a Phase II ready repositioned small molecule immunomodulator for severe influenza and a portfolio of other exciting assets. The Company plans to broaden this portfolio further rapidly post IPO and has already generated an exciting pipeline of potential acquisitions.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma said: “The IPO and funds raised have provided a great platform to begin our rapid growth plan. With experienced management on board and the exciting assets acquired from Open Orphan, we look forward to delivering value to our shareholder base.”

“Our capital light model versus conventional biotech has been well received by investors and we intend to drive business development and product in-licensing and acquisition which will provide continued momentum for our shareholders in the aftermarket and beyond. Underlying the business is our aim to be patient-focused and customer-led and to use our extensive network to become a ‘one-stop shop’ for big pharma, developing and partnering the infectious disease assets that they need.”

Cathal Friel, Chairman of Poolbeg Pharma commented: "Poolbeg Pharma’s approach to asset development should result in monetisation opportunities and excellent returns in a relatively short period of time with substantially less risk than the conventional biotech model while also ensuring regular investor newsflow. At Poolbeg we have assembled a leading management team, generated an exciting pipeline of potential acquisitions and entered active and productive discussions with leading AI data analysis platforms and the IPO will allow Poolbeg to accelerate all of these activities to create shareholders value. 
Thus, I am confident and excited in the Company's prospects going forward and I am delighted to have invested £500,000 alongside incoming investors as part of the IPO.”

The Poolbeg Pharma Board of Directors consists of:

  • Cathal Friel (Non-Executive Chairman)
  • Jeremy Skillington (Chief Executive Officer)
  • Ian O’Connell (Chief Financial Officer
  • Patrick Ashe (Non-Executive Director)
  • Edward Gibson (Non-Executive Director)
  • Luke O’Neill (Non-Executive Director)

finnCapp acts as Nominated Advisor and Joint Broker to Poolbeg Pharma. Arden Partners and J&E Davy act as Joint Brokers.

Quick facts

Market: AIM
Instrument market cap (£m)
Listing/Admission to trading
19 Jul 2021
Looking for new and recent issues?

More recent

London Stock Exchange welcomes HydrogenOne Capital Growth plc to the Premium Segment of the Main Market

HydrogenOne Capital Growth plc, the first London listed hydrogen fund, offers growth potential in clean hydrogen and related technologies. The Company offers investors diversified exposure to private equity and listed hydrogen companies on an international basis. The Company has today listed on the premium segment of London Stock Exchange's main market and qualifies for the Green Economy Mark.<

Learn more
London Stock Exchange welcomes Seplat Energy’s Capital Markets Day

Seplat Energy has today opened London Stock Exchange trading at an official Market Opening ceremony. 

Seplat Energy is a leading independent energy company operating in the prolific Niger Delta area of Nigeria and a leading supplier of processed gas to the domestic market. In 2014 the company completed the first ever dual listing on both the London Stock Exchange (LSEG) and

Learn more
London Stock Exchange welcomes Spinnaker Acquisitions Plc to the Main Market

Spinnaker Acquisitions Plc (“SPAQ”) is a newly established purpose-built cash shell aiming to support businesses and projects in the areas of Sustainability and Energy Transition. With interest in the green economy as keen as it is currently, the objective is to find a business valued at £5–30M with strong profit potential and likely market appetite. 

SPAQ is a company co-founded

Learn more
London Stock Exchange welcomes BIG TECHNOLOGIES PLC to AIM

Big Technologies PLC, the UK-based, remote people monitoring technology company, has today taken the next step in its long-term growth strategy as it is admitted to AIM of London Stock Exchange. It is now trading on AIM, having raised gross proceeds in excess of £200 million, with ticker BIG. At the placing price of 200p per share, Big Technologies PLC has a market capitalisation of £577 millio

Learn more